Blueprint Medicines projects a $4 billion peak revenue opportunity for its systemic mastocytosis (SM) franchise, driven by AYVAKIT's success and updated SM prevalence estimates.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.